Cases & Deals

  • Home
  • Practices
  • OncoHoldings negotiates exclusive license for family of cancer compounds from TGen

Share

OncoHoldings negotiates exclusive license for family of cancer compounds from TGen

April 2011

Client(s) OncoHoldings, Inc.

Jones Day represented OncoHoldings, Inc. in connection with an exclusive license of a family of small molecule selective inhibitors of Histone Deacetylases (HDAC) by the non-profit Translational Genomics Research Institute (TGen).

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.